In 1977 Pietras and Szego \[[@B1]\] showed that plasma membranes prepared from endometrial and liver cells contain a high-affinity estrogen-binding site, but this work was largely ignored by breast cancer researchers and dismissed as a result of experimental artifact due to contamination of the membrane preparations with estrogen receptor (ER)-α. Recent studies examining the identity of the membrane-bound estrogen receptor (mER) have diverged into two schools of thought, the first being that the mER is in fact the classical nuclear ER-α (and ER-β) relocated to the plasma membrane \[[@B2],[@B3]\]; the second proposes that an orphan G-protein-coupled receptor (GPCR) protein \'GPR30\' is the mER \[[@B4],[@B5]\].

In the \'classic ER at the cell surface camp\', Levin and colleagues (for review, see Evinger and Levin \[[@B3]\]) suggested that the rapid effects of estrogen are mediated by a subpopulation of the nuclear ER-α and ER-β proteins, shuttled to the plasma membrane by the scaffold protein caveolin-1, and complexed with multiple signaling molecules, which then functions as an atypical GPCR. Although their data are intriguing and suggest that classical ERs may play a role in cellular signaling outside the nucleus, this model is hard to reconcile with other findings, such as the rapid effects of estrogen on mouse hippocampal neurons from ER-knockout mice.

There is a growing body of evidence suggesting that mER is distinct from ER-α and ER-β, culminating in two recent papers showing that an orphan GPCR, expression of which tends to correlate with that of ER-α, binds directly to and can be activated by estrogen \[[@B4],[@B5]\]. This receptor, called GPR30, may be involved in eliciting some of the effects of 17β-estradiol that were previously attributed to interactions with ER-α and ER-β. The GPCRs as a group have perhaps not been given the attention they deserve by many breast cancer researchers because they are mostly viewed as regulators of various ion channels and not directly involved in cellular growth or differentiation. However, recent studies have shown that GPCRs can influence cellular proliferation and do so by transactivating growth factor receptors including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor, and insulin-like growth factor-1 receptor. This highlights the important role that this class of receptor probably plays, both in normal mammary biology and in the etiology and progression of breast cancer. Interestingly, the estrogen-induced transactivation of EGFR that Levin\'s group attributes to the classical ER-α at the plasma membrane \[[@B2]\] has also been shown to be mediated by GPR30 \[[@B6]\]. Crosstalk between GPR30 and EGFR is due to the rapid proteolytic release of heparin-bound epidermal growth factor by matrix metalloproteases, which allows the ligand to bind to and activate EGFR.

Originally identified in a screen for neurotransmitter receptors in a Burkitt\'s lymphoma cell line, GPR30 was independently cloned in 1997 by Weigel and colleagues \[[@B7]\], who were conducting a differential screen of an MCF-7 cDNA library in an attempt to identify genes overexpressed in ER-positive versus ER-negative breast cancers. They mapped GPR30 to chromosome 7p22; its 2604 base pair transcript contains a 1126 open reading frame that encodes a 375 amino acid protein, expression of which correlates with ER-α in breast cancer cell lines and primary breast carcinomas. GPR30 has significant sequence homology to the angiotensin II 1A, interleukin 8A, and chemokine type 1 receptors, suggesting that the protein might be the receptor for a peptide or glycoprotein, although no such ligand has been found. Others have shown that GPR30 is expressed in estrogen-responsive tissues including breast, heart, leukocytes, brain, and vascular endothelium (for review, see Filardo \[[@B8]\]).

The involvement of GPR30 in estrogen signaling was first demonstrated by Filardo and coworkers \[[@B6]\] in 2000, when they showed that estrogen-induced Erk-1/2 activation was independent of known estrogen receptors. Although others have demonstrated that this occurs in MCF-7 cells, Filardo and colleagues showed that it also occurs in ER-α/β-negative, GPR30-positive SKBR3 cells. Furthermore MDA-MB-231 cells, which are GPR30-negative due to a genomic deletion, are converted to an estrogen-responsive phenotype by transfection with GPR30. Interestingly, they also showed that the pure antiestrogen ICI 182,780 functions as an agonist toward GPR30.

Although GPR30 was shown to be involved in the rapid nongenomic effects of estrogen, it was not known whether estrogen interacted directly with the GPCR or indirectly through an unknown mER. Two nearly simultaneous reports finally put this to rest, demonstrating that estrogen binds directly to GPR30, making this protein a strong candidate for the mER \[[@B4],[@B5]\]. Thomas and coworkers \[[@B5]\] found that estrogen binds to GPR30 with a K~d~of 2.7 nmol/l, and that it is a displaceable receptor with a single saturable binding site. This work was conducted using the SKBR-3 cell line and an ER-α/ER-β/GPR30-negative embryonic kidney cell line, which only acquires estrogen-binding activity after transfection with a GPR30 expression construct. In addition, they demonstrated that tamoxifen and ICI 182,780 bind to GPR30 and appear to mimic the effects of estrogen. The effects of ICI 182,780 are interesting, given the fact that this compound has always been considered a pure antiestrogen. These recent discoveries, coupled with the known actions of GPR30 and its apparent coexpression in ER-α-positive breast cancers and estrogen-responsive tissue, make it an excellent candidate for being the true mER.

The work by Thomas and coworkers was confirmed by Revankar and colleagues \[[@B4]\], who showed that GPR30 binds to estrogen and fluorescent estrogen derivatives, and that this binding results in increased intracellular calcium and phosphatidylinositol 3,4,5-triphosphate. Although these two groups concur on the estrogen-binding characteristics of GPR30, they disagree on its cellular localization. Thomas and coworkers believe that GPR30 is located at the plasma membrane, whereas the findings reported by Revanker and colleagues \[[@B4]\], using a fluorescently linked GPR30, suggest that it is located within the endoplasmic reticulum -- a conclusion apparently supported by additional studies using a fluorescent marker to locate native GRP30 in several cell lines. These data, which seem to contradict previous studies of GPR30 subcellular distribution, may have added to some of the confusion as to whether GPR30 is indeed the true mER. Nevertheless, the identification, characterization, and demonstration of the estrogen-binding characteristics of GPR30 certainly merit serious consideration by breast cancer researchers that it is a potentially important player in estrogen signaling in the breast.

In conclusion, the literature is replete with studies demonstrating that estrogen can produce a panoply of effects in cells, such as alterations in calcium flux, activation of adenyl cyclase, mitogen-activated protein kinase, among others, that in other systems are seen as a result of the activation of GPRCs. The assumption heretofore has been that these effects were most likely mediated by the canonical ERs (ER-α and ER-β); however, given that in most cases the culture systems used also express GPR30, this assumption needs to be tested. It may be that a better understanding of the role played by GPR30 in global estrogen signaling will provide insight into some of the most challenging and longstanding questions in breast cancer research, such as how estrogen signaling is involved in mammary carcinogenesis, the relationship between estrogen responsive and refractory disease, and the mechanisms by which previously hormone responsive tumors elude that control.
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